



YOUR VISION IS OUR VISION™

## Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project

October 22, 2018

**Leuven, Belgium, 22 October 2018** – [Oxurion NV](#) (Euronext Brussels: OXUR - *formerly known as ThromboGenics*), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today it is extending its partnership with [Retina Global](#), an international nonprofit organization focused on sustainable outcomes to retinal disease management in underserved areas around the world. Oxurion will support Retina Global's Bolivian Diabetic Retinopathy Project (BOLDR), committed to reducing the number of people going blind due to the increasing prevalence of diabetic retinopathy (DR) in Bolivia. The company will also join Retina Global as a corporate partner at an industry meeting hosted at the [American Academy of Ophthalmology's 2018 annual meeting](#) (AAO 2018) in Chicago.

The BOLDR project, supported by the [World Diabetes Foundation](#) and Oxurion, is focused on increasing DR screening and providing treatment to individuals with diabetic eye disease in Cochabamba, Bolivia and its surrounding areas, with plans for expansion into other cities. As a part of the initiative, retina specialists from the Americas and Europe will visit the city every two months to provide clinical care to patients with DR. Further, the program will provide training and certification courses, instruments and infrastructure to local ophthalmologists to increase patient access to vision-preserving therapies for diabetic eye disease.

The Retina Global Reception at AAO 2018 will bring together retina specialists, ophthalmologists and industry leaders who are committed to improving treatment options and clinical care for individuals with retinal diseases. The event will take place in Chicago, Illinois on Friday, Oct. 26, 2018. For more information, please contact [info@retinaglobal.org](mailto:info@retinaglobal.org).